Published in J Antimicrob Chemother on March 01, 1986
Infections in solid-organ transplant recipients. Clin Microbiol Rev (1997) 2.86
Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother (1991) 2.40
Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob Agents Chemother (2004) 1.79
New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev (2000) 1.75
Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother (1989) 1.41
Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother (1989) 1.21
Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrob Agents Chemother (1989) 1.15
Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob Agents Chemother (1989) 1.13
Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients. Antimicrob Agents Chemother (1992) 1.07
Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother (1993) 1.01
Antiviral therapy: current concepts and practices. Clin Microbiol Rev (1992) 0.96
Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother (1990) 0.91
Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir. Antimicrob Agents Chemother (1999) 0.88
Human cytomegalovirus infection. Thorax (1989) 0.88
Current status of renal transplantation. West J Med (1990) 0.81
Increased efficacy of phosphonoformate and phosphonoacetate inhibition of herpes simplex virus type 2 replication by encapsulation in liposomes. Antimicrob Agents Chemother (1988) 0.77
Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet. Antimicrob Agents Chemother (1995) 0.77
Age-related differences in pharmacokinetics of phosphonoformate in cats. Antimicrob Agents Chemother (1990) 0.75
The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol (2003) 4.62
Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med (2007) 3.02
Successful liver transplantation from crossmatch-positive donors. Transplant Proc (1981) 2.80
Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet (1999) 2.74
Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant (2010) 2.56
Liver transplantation, 1980, with particular reference to cyclosporin-A. Transplant Proc (1981) 2.49
Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia (2007) 2.35
Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol (1992) 2.14
HLA-matching and pretransplant blood transfusions in cadaveric renal transplantation--a changing picture with cyclosporin. Lancet (1986) 2.08
Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol (1998) 2.06
Severe and common side-effects of amphotericin B lipid complex (Abelcet) Bone Marrow Transplant (1998) 2.05
Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol (1987) 1.99
Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood (1990) 1.98
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant (2011) 1.82
Polyclonal antibody secretion in human lymphocytes induced by killed staphylococcal bacteria and by lipopolysaccharide. Scand J Immunol (1977) 1.82
Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet (1998) 1.80
An interchangeable ELISA for cytomegalovirus antigen and antibody. J Virol Methods (1981) 1.80
FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. Transplantation (1994) 1.80
Virus-specific antibody activity of different subclasses of immunoglobulins G and A in cytomegalovirus infections. Infect Immun (1983) 1.78
Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood (1992) 1.77
Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci U S A (1992) 1.77
Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett (1991) 1.73
HLA compatibility and liver transplant outcome. Improved patient survival by HLA and cross-matching. Transplantation (1994) 1.71
Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS (1990) 1.71
Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet (1993) 1.68
Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol (2004) 1.66
Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant (1990) 1.65
Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation (1988) 1.61
Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics. J Med Virol (1989) 1.61
Intraosseous compared to intravenous infusion of allogeneic bone marrow. Bone Marrow Transplant (1998) 1.58
De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant (2014) 1.57
Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. J Acquir Immune Defic Syndr (1992) 1.57
No impact of NOD2/CARD15 on outcome after SCT. Bone Marrow Transplant (2008) 1.56
Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG) Br J Haematol (1990) 1.56
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant (2004) 1.55
Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant (2003) 1.54
Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis (1990) 1.54
Virus-specific immunoglobulin G subclasses in herpes simplex and varicella-zoster virus infections. J Clin Microbiol (1984) 1.53
Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections. J Med Virol (1987) 1.52
Graft-versus-host disease in a liver transplant recipient. Ann Intern Med (1992) 1.52
Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood (1998) 1.51
Influence of cells and virus multiplicity on the inhibition of herpesviruses with acycloguanosine. Intervirology (1980) 1.50
Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. A word of caution in light of the expanding use of this 'steroid-sparing' agent. Arch Intern Med (1990) 1.50
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother (1991) 1.50
Parvovirus B19 infection: association with third-trimester intrauterine fetal death. BJOG (2000) 1.47
Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol (2007) 1.46
Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation. Bone Marrow Transplant (2004) 1.45
Sequence variation within three important cytomegalovirus gene regions in isolates from four different patient populations. J Clin Microbiol (1998) 1.43
Inflammatory cells in transplanted kidneys are infected by human cytomegalovirus. Am J Pathol (1988) 1.41
Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia. Br J Haematol (1994) 1.41
Dynamic changes in HIV-1 quasispecies from azidothymidine (AZT)-treated patients. FASEB J (1992) 1.41
Brief report: donor-derived long-term multilineage hematopoiesis in a liver-transplant recipient. N Engl J Med (1993) 1.40
Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera. J Virol (1992) 1.39
Resin hemoperfusion in chloroquine poisoning. J Toxicol Clin Toxicol (1982) 1.39
Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant (2003) 1.39
Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg (2004) 1.39
American Society of Transplant Surgeons' White Paper: impact of closed ICUs on transplant patients' care. Am J Transplant (2011) 1.38
Combined liver-kidney transplantation: analysis of patients with preformed lymphocytotoxic antibodies. Transplant Proc (1988) 1.38
Transplantation of peripheral blood progenitor cells from unrelated donors. Transplantation (1998) 1.37
Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochim Biophys Acta (1982) 1.33
Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J Virol (1993) 1.32
Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: beneficial effect of low doses in early post-transplantation period. Lancet (1984) 1.31
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1998) 1.30
Diagnosis of infectious mononucleosis by the monospot test. Am J Clin Pathol (1969) 1.28
Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis (1986) 1.28
Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. Cytotherapy (2009) 1.27
Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant (1998) 1.27
Characterisation of a linear binding site for a monoclonal antibody to hepatitis B core antigen. J Med Virol (1991) 1.26
Deterioration in glucose metabolism in pancreatic transplant recipients given cyclosporin. Lancet (1983) 1.26
Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. J Infect Dis (1990) 1.25
Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis (1985) 1.25
Inhibiting effect of (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine on varicella-zoster virus replication in cell culture. Antimicrob Agents Chemother (1987) 1.25
Treatment of hepatic epithelioid hemangioendothelioma with liver transplantation. Cancer (1988) 1.22
Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome. J Infect Dis (1986) 1.22
Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant (2008) 1.22
Variations in the cytomegalovirus major immediate-early gene found by direct genomic sequencing. J Clin Microbiol (1992) 1.22
Drainage of thoracic duct lymph in renal transplant patients. Transplantation (1976) 1.21
Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction. Transfusion (1997) 1.21
A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization. J Virol (1990) 1.21
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol (2006) 1.21
IgG antibodies to human herpesvirus-6 in children and adults and in primary Epstein-Barr virus infections and cytomegalovirus infections [corrected]. J Virol Methods (1988) 1.20
Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. J Infect Dis (1992) 1.20
Is liver transplantation indicated for cholangiocarcinoma? Am J Surg (1993) 1.20
A novel method for determining the sensitivity of herpes simplex virus to antiviral compounds. J Virol Methods (1983) 1.19
A new peptide for human parvovirus B19 antibody detection. Scand J Infect Dis (1989) 1.19